Matches 251 - 300 out of 443 < 1 2 3 4 5 6 7 8 9 >
Match Document Document Title
6250469 Formulations for protection of peg-interferon alpha conjugates  
The present invention provides formulations that prevent loss and damage of PEG-interferon alpha conjugates during and following lyophilization. The formulations of the present invention protect...
6248546 Assay of IGFBP complex  
A method of assaying the growth hormone status of an individual by immuno-assay for the 150 KDa Insulin-like Growth Factor ternary complex (IGF/IGFBP-3/ALS). Alternatively, a binary complex may be...
6245894 Reshaped human antibody to human interleukin-8  
A reshaped human antibody is characterized as having the same binding affinity for IL-8 as a chimeric antibody but with low immunogenicity in comparison. The reshaped antibody has the following...
6238666 RANTES homolog antibody  
The present invention provides a polynucleotide (PTEC) isolated from a prostate cDNA library which identifies and encodes a human rantes homolog (PTEC). The invention provides for genetically...
6235281 Use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6  
The invention relates to the use of TNF antagonists for producing drugs for the treatment of disorders characterized by elevated serum levels of interleukin-6.
6232447 Antibody immunoreactive with a human cytokine designated LERK-6  
The invention is directed to antibodies immunoreactive with a Human LERK-6 as a purified and isolated protein, the DNA encoding the LERK-6, host cells transfected with cDNAs encoding LERK-6.
6232087 Selective immunoassay for IL-Lβ  
The subject invention concerns a novel selective, sensitive, and highly reliable immunoassay for detecting human IL-1β in cultured mononuclear cells or human body fluids. It is a competitive...
6218515 Cyclin E variants and use thereof  
The present invention is directed to nucleic acid molecules encoding a truncated human cyclin E protein, the truncated human cyclin E protein being a constitutively active form of human cyclin E...
6214343 Prevention and treatment of necrotizing enterocolitis  
Methods are described for preventing and treating necrotizing enterocolitis in animals, including humans. Antibodies directed to PAF and/or TNF are shown to have a beneficial effect in animal...
6191261 Growth differentiation factor-9 antibodies and methods  
Growth differentiation factor-9 (GDF-9) is disclosed along with its polynucleotide sequence and amino acid sequence. Also disclosed are diagnostic and therapeutic methods of using the GDF-9...
6184359 Antibodies to epithelium-derived T-cell factor  
Nucleic acid sequences which encode biologically active ETF, expression vectors which direct the expression of ETF, ETF polypeptides, antibodies which specifically bind ETF and processes for...
6183971 Human betacellulin-specific antibodies and uses thereof  
Disclosed are an antibody which have a binding activity to human betacellulin protein or a mutein thereof with specificity; especially a monoclonal antibody which does not have cross reactitivity...
6169167 Antibodies to ligands for HEK4 receptors  
Polypeptides which bind to one or more EPH-like receptors, particularly the HEK4 receptor, are described. The polypeptides are designated HEK4 binding proteins. Nucleic acids encoding HEK4 binding...
6168791 Antibodies that bind immunomodulators  
This invention relates to a polypeptide other than human interleukin (10) which has at least one of the following properties: a) induces inhibition of spontaneous IL-8 production by human...
6166185 Antibodies to human TIE-2 ligands  
The present invention provides for an isolated nucleic acid molecule encoding a human TIE-2 ligand. In addition, the invention provides for a receptor body which specifically binds a human TIE-2...
6146630 Inhibitors for the adhesion of lymphocytes to glandular cells  
The present invention provides adhesion inhibitors for suppressing the adherence between E-cadherin of glandular cells and integrin of lymphocytes. Sjogren's syndrome comprises disorders wherein...
6133426 Humanized anti-IL-8 monoclonal antibodies  
Humanized anti-IL-8 monoclonal antibodies and variants thereof are described for use in diagnostic applications and in the treatment of inflammatory disorders. Also described is a conjugate formed...
6123941 Method for restoration of normal phenotype in cancer cells  
A method for reversing expression of malignant phenotype in cancer cells is described. The method comprises applying β 1 integrin function-blocking antibody to the cells. The method can be used...
6096871 Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life  
Polypeptides that are cleared from the kidney and do not contain in their original form a Fc region of an IgG are altered so as to comprise a salvage receptor binding epitope of an Fc region of an...
6090923 Murine monoclonal antibody binding TNFα  
A cytotoxic protein expressed by human peripheral blood mononuclear cells is isolated in essentially homogenous form. This protein may be used to elicit production of polyclonal or monoclonal...
6084075 Agonist and antagonist antibodies to the chemokine receptor-2 (CCR2)  
The invention relates to antibodies which is capable of binding the monocyte chemoattractant protein 1 (MCP-1) receptor CCR2, especially those which are capable of acting either as an antagonist or...
6083501 Drug for prevention and therapy of diseases caused by fibrinoid formation or thrombus formation in the lung and model animals of the diseases  
A drug for prevention and therapy of diseases caused by fibrinoid formation or thrombus formation, as well as a model animal of fibrinoid formation or thrombus formation in the lung is disclosed....
6080407 Diagnostic assays for MIF  
The present invention relates to compositions and methods for inhibiting the release and/or biological activity of migration inhibitory factor (MIF). In particular, the invention relates to the...
RE36755 DNA encoding tumor necrosis factor-α and -β receptors  
Tumor necrosis factor receptor DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
6068841 Antibodies to Fas-L for treatment of hepatitis  
The invention provides therapeutic agents for hepatitis, comprising an antibody against a human Fas ligand, or an active fragment thereof as an active ingredient. The therapeutic agents for...
6068840 Recombinant CDR-grafted and chimeric anti-IL-8 antibodies containing CDRs or the variable region from the mouse monoclonal antibody, WS-4  
Monoclonal antibodies immunospecific for the neutrophil chemotactic factor, IL-8, have been humanized by reshaping the variable regions to conform more closely to human counterparts. These...
6063586 Diagnostic protocol  
A cancer prognostic having particular utility in the prognosis of head and neck squamous cell cancer, in which the expression levels of either or both of Transforming Growth Factor Alpha (TGF-α)...
6057427 Antibody to cytokine response gene 2(CR2) polypeptide  
Disclosed are an isolated antibody or antibody fragment that selectively binds a polypeptide encoded by Cytokine Response gene 2 (CR2), and in particular, selectively binds to a first polypeptide...
6056957 Humanized monoclonal antibodies against human interleukin-5  
A monoclonal antibody is provided which specifically binds to human interleukin-5. Also provided are a hybridoma which produces the monoclonal antibody; complementary DNAs which encode the heavy...
6045795 Methods and compositions for ameliorating the symptoms of sepsis  
The present invention concerns a method of treating sepsis comprising administering a therapeutically effective amount of anti-CD14 antibody molecules. A therapeutic composition comprising...
6043086 Neurotactin and uses therefor  
The present invention relates to the identification and characterization of a novel, membrane-anchored chemokine, neurotactin. Sequence analysis of neurotactin reveals that, while it includes an...
6036956 Method and dosage form using an antagonist to gamma interferon to control MHC-associated autoimmune disease  
The present invention is directed to immunotherapeutic methos for treating systemic lupus erythematosus (SLE) by administerring polyclonal or monoclonal antibodies specific for gamma interferon...
6030615 Combination method for treating diseases caused by cytokine-mediated toxicity  
There is disclosed a method for treating an individual having a disease caused by cytokine-mediated toxicity comprising administering to the individual an effective amount of (a) an antibody that...
6025475 Growth differentiation factor-3  
Growth differentiation factor-3 (GDF-3) is disclosed along with its polynucleotide sequence and amino acid sequence. Also disclosed are diagnostic and therapeutic methods of using the GDF-3...
6025143 Antibodies directed against peptides derived from the SMR1 polypeptide  
The present invention relates to peptides and polypeptides derived from the submaxillary gland of the rat. In particular, the present invention discloses a purified peptide of formuls: ...
6024956 Method to treat inflammation with humanized anti-IL-8-antibodies  
Monoclonal antibodies immunospecific for the neutrophil chemotactic factor, IL-8, have been humanized by reshaping the variable regions to conform more closely to human counterparts. These...
6019969 Composition comprising antibody to macrophage-derived inflammatory mediator (MIP-α 1 and MIP-1β)  
An inflammatory cytokine is disclosed which has been isolated from cells that have been incubated with a stimulator material. The inflammatory cytokine comprises a protein that is capable of...
6015559 Fas antagonists  
The present invention provides a panel of monoclonal antibodies and binding proteins which specifically bind to human Fas antigen. Some of the antibodies and binding proteins are capable of...
6001357 Method of enhancing wound healing with anti-IL-5 antibody  
The invention provides a method of enhancing wound healing, comprising administering an inhibitor of eosinophil influx into a wound site sufficient to result in healing of the wound.
5998378 Compositions for the inhibition of TNF hormone formation and uses thereof  
Compounds having proteolytic inhibitory activity useful for treating diseases, particularly as applied to the treatment of sepsis, AIDS or autoimmune diseases, resulting from a decrease in the...
5994524 Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same  
The present invention discloses a reshaped human antibody against human IL-8 comprising: (A) L chains each comprising: (1) a human L chain C region; and, (2) an L chain V region comprising...
5981713 Antibodies to intereleukin-1 antagonists  
A novel interleukin-1 antagonist active against both IL-1α and IL-1β and DNA encoding same/re described. Antibodies specific for the novel IL-1 antagonist and prophylatic, therapeutic and...
5977323 Method of purifying Gro β or Gro α protein using antibodies  
Two novel cytokines which are involved in an inflammatory response (inflammatory cytokines) are disclosed. The inflammatory cytokines have been isolated from activated peripheral blood, preferably...
5972718 Method of detecting heparin-induced thrombocytopenia  
A method of detecting heparin-induced antibodies to complete a diagnosis of heparin-induced thrombocytopenia HITP is disclosed. In one embodiment, this method comprises binding human platelet...
5969107 Anti-idiotypic antibodies which induce an immune response against epidermal growth factor receptor  
The present invention relates to anti-idiotypic antibodies which induce an immune response against tumors, bearing as antigen the epidermal growth factor receptor (EGFR). The antibodies of the...
5969110 Antibodies that bind hek ligands  
Antibodies specific for a hek-L may be generated, using a hek-L polypeptide or fragment thereof as an immunogen. The antibodies may be monoclonal.
5959085 Human monoclonal antibodies against human cytokines and methods of making and using such antibodies  
Human monoclonal antibodies against a human cytokine (such as a human interleukin, e.g., human IL-1α) and fragments of such antibodies are disclosed. Also disclosed are pharmaceutical compositions...
5958413 Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor  
A combined preparation for simultaneous combined, simultaneous separate, or sequential use in the therapy of prophylaxis of disorders associated with undesirable high levels of TNF, e.g. septic or...
5939280 Immunological assay for quantifying peg-modified human granulocyte colony stimulating factor and monoclonal antibodies used in the assay  
An immunological assay for quantifying PEG-modified human granulocyte colony stimulating factor or derivatives thereof in a sample comprising bringing into contact with said sample an antibody...
5929213 Antibodies to growth differentiation factor-12  
Growth differentiation factor-12 (GDF-12) is disclosed along with its polynucleotide sequence and amino acid sequence. Also disclosed are diagnostic and therapeutic methods of using the GDF-12...
Matches 251 - 300 out of 443 < 1 2 3 4 5 6 7 8 9 >